Gefitinib plus interleukin-2 in advanced non-small cell lung cancer patients previously treated with chemotherapy. - Wikidata - awgldk - TriplyDB

Gefitinib plus interleukin-2 in advanced non-small cell lung cancer patients previously treated with chemotherapy.

Gefitinib plus interleukin-2 in advanced non-small cell lung cancer patients previously treated with chemotherapy.

http://www.wikidata.org/entity/Q34774866

about

The past, present and future of immunotherapy against tumor The Utilization of the Immune System in Lung Cancer Treatment: Beyond Chemotherapy NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy.Role of IL-2 in cancer immunotherapy

P2860

Q26799896-5BF1CB3E-CDB7-41DA-B6A5-24B55C112792 Q28066568-34A81235-C5CA-4C2C-92D1-23DBD518FBCB Q35059990-1E4DA2BA-E4BB-4732-AFDE-43FEB43DC994 Q37079072-5321D77E-841A-440A-8904-4BDED94B4106

P2860

Gefitinib plus interleukin-2 in advanced non-small cell lung cancer patients previously treated with chemotherapy.

http://www.wikidata.org/entity/Q34774866

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Gefitinib plus interleukin-2 i ...... sly treated with chemotherapy.

@ast

Gefitinib plus interleukin-2 i ...... sly treated with chemotherapy.

@en

Gefitinib plus interleukin-2 i ...... sly treated with chemotherapy.

@nl

type

label

Gefitinib plus interleukin-2 i ...... sly treated with chemotherapy.

@ast

Gefitinib plus interleukin-2 i ...... sly treated with chemotherapy.

@en

Gefitinib plus interleukin-2 i ...... sly treated with chemotherapy.

@nl

prefLabel

Gefitinib plus interleukin-2 i ...... sly treated with chemotherapy.

@ast

Gefitinib plus interleukin-2 i ...... sly treated with chemotherapy.

@en

Gefitinib plus interleukin-2 i ...... sly treated with chemotherapy.

@nl

P1433

Q34774866-EF1B5FB0-8C4A-477F-B5A3-D5038ABEF69D

P1476

Q34774866-BA04CC0C-CD0B-4D45-82F4-5EB8B9264B36

P2093

Q34774866-16366AF0-B19D-42A5-BB79-96AD9A706B30

Q34774866-29320B50-521E-4501-BC87-7E0597D51372

Q34774866-614239CB-F225-409E-9AF4-027BE055F3F7

Q34774866-78B4E4DD-AC4A-455A-9793-D7EEDD97B4E0

Q34774866-E7D76FDE-B59C-4C29-B7C1-62C89D9AAB4B

P2860

Q34774866-01327D19-AEE6-4E19-AA31-08FCF15EEC31

Q34774866-1465717C-5DD0-4FA1-90BE-2DE408943F07

Q34774866-15A05E77-1346-458B-BCE8-9F94B3DD5EE9

Q34774866-1A6BD0DB-439F-4DBE-8676-6B090DEF36A8

Q34774866-1CE4E644-052C-4E3D-9449-2AEF1912C811

Q34774866-20010615-B3FB-4C06-B4DF-1180D81505F2

Q34774866-20BE8479-D54A-4931-9A68-EEFE9229D8BE

Q34774866-22C0EC8E-2CCE-47E4-B06E-59A0CDDF9FD7

Q34774866-23CBE4F1-747B-4A30-B511-327295C75012

Q34774866-26BB8E2B-82A5-4F8C-B350-CCB9D243748A

P304

Q34774866-CF4DDE25-8E71-4FD3-9FBB-0BED56E2094B

P31

Q34774866-53827292-B539-4FD3-89AF-E338F0043396

P356

Q34774866-0B2244B8-0C60-4BE0-BBBA-B3B8C8CE46BD

P433

Q34774866-6BF9AD57-618E-49EE-A1FC-C39C43F4AB48

P478

Q34774866-EA8625DD-73D0-4902-B898-D1537B8F93ED

P50

Q34774866-23CA1B9F-0845-4A25-AF8E-AD0417BF3F4D

Q34774866-87F3E874-2E85-46AA-BE02-23E44D9563F9

P577

Q34774866-EC08666A-5C48-4990-B7E9-EBBDDA693865

P5875

Q34774866-0CB43EF2-307C-4ADE-871F-C4D8B437F7F6

P698

Q34774866-9256AE78-DD06-4D37-B5AD-E1927A7F25C2

P921

Q34774866-9FBB2593-39FC-4351-B314-759C1587CD52

P932

Q34774866-8D23696A-C781-4403-AC0F-33F791222008

P356

P1433

P1476

Gefitinib plus interleukin-2 i ...... usly treated with chemotherapy

@en

P2093

Giancarlo Mazza

http://www.w3.org/2001/XMLSchema#string

Matteo Brighenti

http://www.w3.org/2001/XMLSchema#string

Roberta Camisa

http://www.w3.org/2001/XMLSchema#string

Rodolfo Passalacqua

http://www.w3.org/2001/XMLSchema#string

Silvia Lazzarelli

http://www.w3.org/2001/XMLSchema#string

P2860

Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis

What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

Interleukin-2 and interferon-alpha in the treatment of patients with advanced non-small-cell lung cancer.

Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: a phase I trial.

Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.

P304

2035-2048

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/CANCERS6042035

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Sebastiano Buti

Melissa Bersanelli

P577

2014-09-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266250914

http://www.w3.org/2001/XMLSchema#string

P698

25271833

http://www.w3.org/2001/XMLSchema#string

P921

P932

4276955

http://www.w3.org/2001/XMLSchema#string